Enterprise Value
574.7M
Cash
71.52M
Avg Qtr Burn
-10.85M
Short % of Float
31.78%
Insider Ownership
0.72%
Institutional Own.
80.60%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNRELEF (bupivacaine and meloxicam) HTX-011 Details Post operative acute pain | Approved Quarterly sales | |
ZYNRELEF (bupivacaine and meloxicam) HTX-011 Details Post operative acute pain | Approved Quarterly sales | |
Cinvanti Details Chemotherapy induced nausea and vomiting | Approved Quarterly sales | |
Sustol Details Chemotherapy induced nausea and vomiting | Approved Quarterly sales | |
APONVIE™ (HTX-019) Details Nausea and vomiting | Approved Quarterly sales | |
ZYNRELEF® Vial Access Needle ("VAN") Details Post operative acute pain | PDUFA Approval decision |